UBS Upgrades Jazz Pharmaceuticals to Buy, Sets $307 Target
UBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
This quick overview presents the typical long-term return profile of total market funds, helping frame diversified retirement and growth goals.
28,588 articlesUBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
Three leading space names moved higher in a risk-on trading session, with AST SpaceMobile, Rocket Lab and Planet Labs...
Bitcoin price drops as the Fed leaves rates steady under new Chair Kevin Warsh, triggering intraday volatility and be...
EWY’s 12-month trajectory hinges on two volatile signals: AI memory demand and the concentration risk tied to Samsung...
IREN is staking its growth on a 1.4 GW Australian AI infrastructure push valued at about $22 billion, anchored by the...
JPMorgan initiates SPX Technologies with an Overweight rating and a $260 target, signalling a favorable view on data-...
Mortgage rates move higher for a second straight week, delaying any spring surge in activity. Analysts say inflation ...
Apple stock just dropped as memory costs surge and device pricing shifts bite into margins. Traders weigh supply-chai...
A prominent investor labels SpaceX’s lofty value as bubblicious, arguing that Starlink’s progress alone may not justi...
Electric-vehicle names rise as a broad tech rebound fuels gains; Tesla jumps 8%, Rivian and Lucid climb about 7% in a...
Carnival sailed to another quarter of record yields, yet its shares lag Royal Caribbean as debt, pricing power, and c...
A scorching June exposes the full cost of FNGU: a 0.95% fee plus stubborn volatility decay from daily leverage resets...